Laboratoire de Virologie, CHU Grenoble Alpes, Grenoble, France; Institut de Biologie Structurale, UMR 5075 CEA-CNRS-Université Grenoble-Alpes, Grenoble, France.
Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France.
Int J Antimicrob Agents. 2023 May;61(5):106769. doi: 10.1016/j.ijantimicag.2023.106769. Epub 2023 Mar 3.
Herpes simplex virus 2 (HSV-2) rarely causes severe disease, even in solid organ transplant recipients. This paper describes a fatal case of HSV-2 infection, probably transmitted from a donor to a kidney transplant recipient. The donor was seropositive for HSV-2 but not for HSV-1, whereas the recipient was seronegative for both viruses before transplantation, suggesting that the graft was the source of infection. The recipient received valganciclovir prophylaxis due to cytomegalovirus seropositivity. Three months after transplantation, the recipient presented with rapidly disseminated cutaneous HSV-2 infection with meningoencephalitis. The HSV-2 strain was resistant to acyclovir, probably acquired under valganciclovir prophylaxis. Despite early initiation of acyclovir therapy, the patient died. This fatal case of HSV-2 infection, probably transmitted by the kidney graft with acyclovir-resistant HSV-2 from the onset, is uncommon.
单纯疱疹病毒 2 型(HSV-2)很少引起严重疾病,即使在实体器官移植受者中也是如此。本文描述了一例 HSV-2 感染的致死病例,可能是由供体传播给肾移植受者。供体血清 HSV-2 阳性但 HSV-1 阴性,而受者移植前两种病毒均为阴性,提示移植物是感染源。由于巨细胞病毒血清阳性,受者接受缬更昔洛韦预防。移植后 3 个月,受者出现迅速播散性皮肤 HSV-2 感染伴脑膜脑炎。HSV-2 株对阿昔洛韦耐药,可能是在缬更昔洛韦预防下获得的。尽管早期开始阿昔洛韦治疗,患者仍死亡。本例 HSV-2 感染致死病例,可能是由肾移植供体携带的、从发病开始就对阿昔洛韦耐药的 HSV-2 传播引起的,较为罕见。